DAP PRESENCE AT THE RX AND ILLICIT DRUG SUMMIT 2024
DAY 02 – Tuesday, 2 April 2024
Day 2 of the #RxSummit2024 began with an impactful Plenary Session featuring a Congressional Panel and Federal Officials. Esteemed speakers included Hal Rogers, U.S. Congressman from Kentucky’s 5th Congressional District; Earl “Buddy” Carter, U.S. Congressman from Georgia’s 1st Congressional District; Nora Volkow, MD, Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health; and Miriam Delphin Rittmon, PhD, Assistant Secretary for Mental Health and Substance Use at SAMHSA.
The excitement and engagement of the exhibition activities extended into Day 2 as well.
DAY 01 – Monday, 1 April 2024
Rx and Illicit Drug Summit stands as the foremost event addressing opioid epidemic, where strategies are shared and put into action. It serves as a platform for leading voices to share strategies with decision-makers and allied professionals, fostering an environment of innovation, and learning about e ective practices in prevention, treatment, recovery, and law enforcement. The Colombo Plan Drug Advisory Programme – DAP proudly holds the position of Titanium Sponsor of the 13th annual Rx Summit taking place from 1 – 4 April 2024 at the Georgia World Conference Center in Atlanta, United States.
Day 1 at #RxSummit2024 kicked off with impactful speeches from U.S. Congressman Hal Rogers, U.S. Department of Justice, Drug Enforcement Administration Administrator Anne Milgram, Director of the National Institutes of Health (NIH) Monica Bertagnolli, and Food and Drug Administration (FDA) Commissioner Robert Cali.
During Day 1, one of the featured events included a compelling presentation by our CEO Thom Browne and Dr. Barry Logan from NMS Labs on ‘It’s not just Fentanyl – The Toxic Adulterant Perspective’.
During the exhibition, The Colombo Plan Drug Advisory Programme – DAP presented details on the Colombo Plan/ CFSRE Sentinel Programme which provides a novel early warning system on emerging, lethal synthetic drugs and complex drug mixtures entering a nation’s local drug supply to better understand epidemics, prevent overdose, and protect the public health of communities worldwide.
